中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
19期
86-87
,共2页
胃癌%替吉奥%卡培他滨%奥沙利铂%化学治疗%毒副反应
胃癌%替吉奧%卡培他濱%奧沙利鉑%化學治療%毒副反應
위암%체길오%잡배타빈%오사리박%화학치료%독부반응
gastric cancer%S-1%capecitabine%oxaliplatin%chemotherapy,adverse reaction
目的：比较卡培他滨或替吉奥（S－1）联合奥沙利铂（L－OHP）治疗进展期胃癌的有效性和安全性。方法收集医院进展期胃癌术后行替吉奥或卡培他滨联合奥沙利铂化疗患者112例的病历资料，其中替吉奥﹢奥沙利铂治疗组（A组）93例，卡培他滨﹢奥沙利铂治疗组（B组）19例，提取病历中患者基础信息、手术、治疗剂量与疗程、完全缓解率、疾病无进展生存期及毒副反应等信息。结果112例患者均可评价疗效，A组、B组的有效率分别为60.22%和68.42%，疾病控制率为83.87%和89.50%，组间差异均无统计学意义（ P﹥0.05）。两组患者毒副反应主要包括血液学毒性、肝肾功能异常、恶心呕吐、腹泻、口腔溃疡等，程度以Ⅰ~Ⅱ度为主，均可耐受。结论卡培他滨或与替吉奥联合奥沙利铂治疗进展期胃癌的疗效相当，毒副反应均可耐受。
目的：比較卡培他濱或替吉奧（S－1）聯閤奧沙利鉑（L－OHP）治療進展期胃癌的有效性和安全性。方法收集醫院進展期胃癌術後行替吉奧或卡培他濱聯閤奧沙利鉑化療患者112例的病歷資料，其中替吉奧﹢奧沙利鉑治療組（A組）93例，卡培他濱﹢奧沙利鉑治療組（B組）19例，提取病歷中患者基礎信息、手術、治療劑量與療程、完全緩解率、疾病無進展生存期及毒副反應等信息。結果112例患者均可評價療效，A組、B組的有效率分彆為60.22%和68.42%，疾病控製率為83.87%和89.50%，組間差異均無統計學意義（ P﹥0.05）。兩組患者毒副反應主要包括血液學毒性、肝腎功能異常、噁心嘔吐、腹瀉、口腔潰瘍等，程度以Ⅰ~Ⅱ度為主，均可耐受。結論卡培他濱或與替吉奧聯閤奧沙利鉑治療進展期胃癌的療效相噹，毒副反應均可耐受。
목적：비교잡배타빈혹체길오（S－1）연합오사리박（L－OHP）치료진전기위암적유효성화안전성。방법수집의원진전기위암술후행체길오혹잡배타빈연합오사리박화료환자112례적병력자료，기중체길오﹢오사리박치료조（A조）93례，잡배타빈﹢오사리박치료조（B조）19례，제취병력중환자기출신식、수술、치료제량여료정、완전완해솔、질병무진전생존기급독부반응등신식。결과112례환자균가평개료효，A조、B조적유효솔분별위60.22%화68.42%，질병공제솔위83.87%화89.50%，조간차이균무통계학의의（ P﹥0.05）。량조환자독부반응주요포괄혈액학독성、간신공능이상、악심구토、복사、구강궤양등，정도이Ⅰ~Ⅱ도위주，균가내수。결론잡배타빈혹여체길오연합오사리박치료진전기위암적료효상당，독부반응균가내수。
Objective To compare the efficacy and safety of capecitabine combined or S-1 combined with oxaliplatin in treating ad-vanced gastric cancer. Methods 112 cases of records with advanced gastric cancer were selected, including 93 cases applying S-1 and oxaliplatin ( group A ) , and 19 cases applying capecitabine combined with oxaliplatin ( group B ) . The basic information, operation treat-ment, dosage and period of treatment, curative effect and adverse reaction information were retrieved from the records. Results 112 cases were all assessable The remission rate of the group A and group B were 60. 22% and 68. 42%, and the disease control rate were 83. 87% and 89. 50% respectively, with no statistically significant difference between the two groups ( P ﹥ 0. 05 ) . The adverse reactions of the two groups included hematological toxicity, liver and kidney dysfunction, nausea and vomiting, diarrhea, oral ulcer, etc. All those were in levels 1-2,and were well tolerated. Conclusion The effect of capecitabine or S-1 combined with oxaliplatin in the treatment of advanced gastric cancer is similar and the adverse reactions could both be tolerable.
